Why FDA Said No to a Melanoma Drug

• by Arthur Allen

• May 15, 2026

Repurposing tricyclic drugs as cancer therapeutics: comparative analysis of antitumorigenic effects of chlorpromazine, amitriptyline and imipramine

• by Joos Berghausen, Eric Glasgow, Tinatin I. Brelidze

• July 2, 2026

Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma

UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.

• June 24, 2026

• 1 min

Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis

• by Rohit Sharma, Rajan P. Kulkarni, Richard Essner, Andrew Ward, Andrew H. Lewis, Shireen Guide, J. Michael Guenther

• June 23, 2026